Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer's disease:a systematic review and meta-analysis  

作　　者：Xulong Ding Shuting Zhang Lijun Jiang Lu Wang Tao Li Peng Lei 

机构地区：[1]Department of Neurology and State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy,National Clinical Research Center for Geriatrics,West China Hospital,Sichuan University,Chengdu 610041,China [2]Department of Neurology,West China Hospital,Sichuan University,Chengdu 610041,China [3]Mental Health Center and West China Brain Research Center,West China Hospital,Sichuan University,Chengdu 610041,China [4]Department of Rehabilitation Medicine,West China Hospital,Sichuan University,Chengdu 610041,China

出　　处：《Translational Neurodegeneration》2021年第1期112-125,共14页转化神经变性病（英文）

基　　金：supported by the Ministry of Science and Technology of China(2018YFC1312300);the National Natural Science Foundation of China(81722016)。

摘　　要：A lack of convenient and reliable biomarkers for diagnosis and prognosis is a common challenge for neurodegenerative diseases such as Alzheimer's disease(AD).Recent advancement in ultrasensitive protein assays has allowed the quantification of tau and phosphorylated tau proteins in peripheral plasma.Here we identified 66 eligible studies reporting quantification of plasma tau and phosphorylated tau 181(ptau181)using four ultrasensitive methods.Meta-analysis of these studies confirmed that the AD patients had significantly higher plasma tau and ptau181 levels compared with controls,and that the plasma tau and ptau181 could predict AD with high-accuracy area under curve of the Receiver Operating Characteristic Therefore,plasma tau and plasma ptau181 can be considered as biomarkers for AD diagnosis.

关 键 词：TAU Phosphorylated tau 181 Alzheimer's disease Simoa IMR EIMAF/a-EIMAF MSD Plasma biomarker 

分 类 号：R749.16[医药卫生—神经病学与精神病学]